Cargando…
A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation
MYC is a key player in tumor development, but unfortunately no specific MYC-targeting drugs are clinically available. MYC is strictly dependent on heterodimerization with MAX for transcription activation. Aiming at targeting this interaction, we identified MYCMI-6 in a cell-based protein interaction...
Autores principales: | Castell, Alina, Yan, Qinzi, Fawkner, Karin, Hydbring, Per, Zhang, Fan, Verschut, Vasiliki, Franco, Marcela, Zakaria, Siti Mariam, Bazzar, Wesam, Goodwin, Jacob, Zinzalla, Giovanna, Larsson, Lars-Gunnar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030159/ https://www.ncbi.nlm.nih.gov/pubmed/29968736 http://dx.doi.org/10.1038/s41598-018-28107-4 |
Ejemplares similares
-
MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent Manner
por: Castell, Alina, et al.
Publicado: (2022) -
The structure of INI1/hSNF5 RPT1 and its interactions with the c‐MYC:MAX heterodimer provide insights into the interplay between MYC and the SWI/SNF chromatin remodeling complex
por: Sammak, Susan, et al.
Publicado: (2018) -
MYC Modulation around the CDK2/p27/SKP2 Axis
por: Hydbring, Per, et al.
Publicado: (2017) -
Crystal Structures and Nuclear Magnetic Resonance
Studies of the Apo Form of the c-MYC:MAX bHLHZip Complex Reveal
a Helical Basic Region in the Absence of DNA
por: Sammak, Susan, et al.
Publicado: (2019) -
Pharmacological inactivation of CDK2 inhibits MYC/BCL-XL-driven leukemia in vivo through induction of cellular senescence
por: Bazzar, Wesam, et al.
Publicado: (2020)